$29.26
-0.87[-2.89%]
At close: Apr 24
$29.26
0[0.00%]
After Hours: 4:00PM EDT
Evolent Health
(NYSE:EVH)Evolent Health Stock (NYSE:EVH), Analyst Ratings, Price Targets, Predictions
Evolent Health Inc has a consensus price target of $43.93, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, Canaccord Genuity, and JP Morgan on April 22, 2024, March 28, 2024, and March 15, 2024. With an average price target of $45.33 between Citigroup, Canaccord Genuity, and JP Morgan, there's an implied 54.93% upside for Evolent Health Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Canaccord Genuity
JP Morgan
Oppenheimer
JMP Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Evolent Health
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | EVH | Buy Now | Evolent Health | $29.26 | 36.71% | Citigroup | Daniel Grosslight | → $40 | Initiates | → Buy | Get Alert |
| 03/28/2024 | EVH | Buy Now | Evolent Health | $29.26 | 50.38% | Canaccord Genuity | Richard Close | $45 → $44 | Maintains | Buy | Get Alert |
| 03/15/2024 | EVH | Buy Now | Evolent Health | $29.26 | 77.72% | JP Morgan | Anne Samuel | $53 → $52 | Maintains | Overweight | Get Alert |
| 03/01/2024 | EVH | Buy Now | Evolent Health | $29.26 | 53.79% | Oppenheimer | Jeff Jones | → $45 | Initiates | → Outperform | Get Alert |
| 02/23/2024 | EVH | Buy Now | Evolent Health | $29.26 | 29.87% | JMP Securities | Constantine Davides | $37 → $38 | Maintains | Market Outperform | Get Alert |
| 02/23/2024 | EVH | Buy Now | Evolent Health | $29.26 | 53.79% | Canaccord Genuity | Richard Close | $47 → $45 | Maintains | Buy | Get Alert |
| 12/06/2023 | EVH | Buy Now | Evolent Health | $29.26 | 26.45% | JMP Securities | Constantine Davides | → $37 | Initiates | → Market Outperform | Get Alert |
| 11/28/2023 | EVH | Buy Now | Evolent Health | $29.26 | 43.54% | RBC Capital | Sean Dodge | $44 → $42 | Maintains | Outperform | Get Alert |
| 11/14/2023 | EVH | Buy Now | Evolent Health | $29.26 | 16.2% | Truist Securities | Sandy Draper | $36 → $34 | Maintains | Hold | Get Alert |
| 10/16/2023 | EVH | Buy Now | Evolent Health | $29.26 | 57.21% | UBS | Kevin Caliendo | → $46 | Initiates | → Buy | Get Alert |
| 08/14/2023 | EVH | Buy Now | Evolent Health | $29.26 | 60.63% | Guggenheim | Sandy Draper | → $47 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | EVH | Buy Now | Evolent Health | $29.26 | 60.63% | Guggenheim | Sandy Draper | $50 → $47 | Maintains | Buy | Get Alert |
| 05/24/2023 | EVH | Buy Now | Evolent Health | $29.26 | 50.38% | RBC Capital | Sean Dodge | → $44 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | EVH | Buy Now | Evolent Health | $29.26 | 36.71% | Stephens & Co. | Jeff Garro | → $40 | Reiterates | → Overweight | Get Alert |
| 04/12/2023 | EVH | Buy Now | Evolent Health | $29.26 | 36.71% | Stephens & Co. | Jeff Garro | → $40 | Initiates | → Overweight | Get Alert |
| 02/23/2023 | EVH | Buy Now | Evolent Health | $29.26 | 50.38% | RBC Capital | Sean Dodge | → $44 | Reiterates | → Outperform | Get Alert |
| 01/30/2023 | EVH | Buy Now | Evolent Health | $29.26 | 101.64% | Cowen & Co. | Charles Ryhee | $57 → $59 | Maintains | Outperform | Get Alert |
| 11/18/2022 | EVH | Buy Now | Evolent Health | $29.26 | 94.81% | Cowen & Co. | Charles Ryhee | $52 → $57 | Maintains | Outperform | Get Alert |
| 11/04/2022 | EVH | Buy Now | Evolent Health | $29.26 | 12.78% | Piper Sandler | Jessica Tassan | $40 → $33 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Evolent Health (EVH)?
The latest price target for Evolent Health (NYSE: EVH) was reported by Citigroup on April 22, 2024. The analyst firm set a price target for $40.00 expecting EVH to rise to within 12 months (a possible 36.71% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evolent Health (EVH)?
The latest analyst rating for Evolent Health (NYSE: EVH) was provided by Citigroup, and Evolent Health initiated their buy rating.
When was the last upgrade for Evolent Health (EVH)?
The last upgrade for Evolent Health Inc happened on November 18, 2021 when JP Morgan raised their price target to $37. JP Morgan previously had a neutral for Evolent Health Inc.
When was the last downgrade for Evolent Health (EVH)?
There is no last downgrade for Evolent Health.
When is the next analyst rating going to be posted or updated for Evolent Health (EVH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evolent Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evolent Health was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating Evolent Health (EVH) correct?
While ratings are subjective and will change, the latest Evolent Health (EVH) rating was a initiated with a price target of $0.00 to $40.00. The current price Evolent Health (EVH) is trading at is $29.26, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.